Table 2. Treatment delivery and dose intensity (N=51).

	Dose of	No. of patients			Median dose intensity (mg m−2 week−1)
Level	irinotecan(mg m−2)	Evaluated	Completed nine cycles	(%)	Projected	Actual	(%)
1	20	6	5	83	8.6	8.6	99
2	40	6	6	100	17.2	17.2	100
3	50	5	5	100	21.6	21.5	100
4	60	5	4	80	25.9	21.3	82
5	70	6	6	100	30.2	27.2	90
6	80	12	10	83	34.5	32.8	95
7	90	7	7	100	38.8	34.5	89
8	100	4	2	50	43.1	30.4	71

Five patients were excluded from this analysis because of progressive disease in four patients and protocol violation in one patient.